CA2458872A1 - Human ubiquitin-conjugating enzyme - Google Patents

Human ubiquitin-conjugating enzyme Download PDF

Info

Publication number
CA2458872A1
CA2458872A1 CA002458872A CA2458872A CA2458872A1 CA 2458872 A1 CA2458872 A1 CA 2458872A1 CA 002458872 A CA002458872 A CA 002458872A CA 2458872 A CA2458872 A CA 2458872A CA 2458872 A1 CA2458872 A1 CA 2458872A1
Authority
CA
Canada
Prior art keywords
conjugating enzyme
human ubiquitin
pharmaceutical composition
antibody
radioisotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002458872A
Other languages
French (fr)
Other versions
CA2458872C (en
Inventor
Masato Horie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Masato Horie
Fujiwara, Tsutomu
Watanabe, Takeshi
Protein Design Labs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP06916397A external-priority patent/JP3646191B2/en
Application filed by Otsuka Pharmaceutical Co., Ltd., Masato Horie, Fujiwara, Tsutomu, Watanabe, Takeshi, Protein Design Labs, Inc. filed Critical Otsuka Pharmaceutical Co., Ltd.
Priority to CA2641565A priority Critical patent/CA2641565C/en
Publication of CA2458872A1 publication Critical patent/CA2458872A1/en
Application granted granted Critical
Publication of CA2458872C publication Critical patent/CA2458872C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a pharmaceutical composition for treating prostate cancer, the pharmaceutical composition comprising an antibody against human TMP-2 protein together with a pharmaceutically acceptable carrier. In one embodiment, the antibody is conjugated to a therapeutic moiety which can be a cytotoxic agent or a radioisotope.
CA002458872A 1996-03-19 1997-03-19 Human ubiquitin-conjugating enzyme Expired - Fee Related CA2458872C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2641565A CA2641565C (en) 1996-03-19 1997-03-19 Nel-related proteins type 1 and 2, and polynucleotides encoding them

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP6341096 1996-03-19
JP63410/1996 1996-03-19
JP69163/1997 1997-03-05
JP06916397A JP3646191B2 (en) 1996-03-19 1997-03-05 Human gene
CA002200371A CA2200371C (en) 1996-03-19 1997-03-19 Human npik gene

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002200371A Division CA2200371C (en) 1996-03-19 1997-03-19 Human npik gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2641565A Division CA2641565C (en) 1996-03-19 1997-03-19 Nel-related proteins type 1 and 2, and polynucleotides encoding them

Publications (2)

Publication Number Publication Date
CA2458872A1 true CA2458872A1 (en) 1997-09-19
CA2458872C CA2458872C (en) 2009-05-19

Family

ID=32474726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002458872A Expired - Fee Related CA2458872C (en) 1996-03-19 1997-03-19 Human ubiquitin-conjugating enzyme

Country Status (1)

Country Link
CA (1) CA2458872C (en)

Also Published As

Publication number Publication date
CA2458872C (en) 2009-05-19

Similar Documents

Publication Publication Date Title
EP0330201A3 (en) Method of enhancing the effect of cytotoxic agents
WO1994004702A3 (en) Improved detection and therapy of lesions with biotin/avidin conjugates
MXPA01011008A (en) Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases.
EP0658111A4 (en) Methods for enhancing drug delivery with modified saponins.
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
ATE245662T1 (en) AVIDIN-BIOTIN IMMUNOCONJUGATES
AP9801392A0 (en) Concentrated antibody preparation.
CA2124218A1 (en) Cytotoxic drug therapy
IL129356A0 (en) Conjugates useful in the treatment of prostate cancer
PT837684E (en) PHARMACEUTICAL COMPOSITIONS BASED ON A DICLOFENAC AND THYOCOLCHOSIDE SALT
MY137303A (en) Methods for treating proliferative diseases
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
CA2135312A1 (en) Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
WO2003045429A3 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
GB9601640D0 (en) Ligand directed enzyme prodrug therapy
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO1999021574A3 (en) Enhancement of morphogen activity
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
AU2193797A (en) Delivery of therapeutic agents to the prostate
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CA2297149A1 (en) 13-deoxyanthracycline derivatives for treating cancer
AU3478600A (en) Treatment of autoimmune diseases with american ginseng extract

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160321